Rob Dillard

DocwireNews

A prediction model may serve as a viable management tool for patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE), according to a new study <a href="https://pubmed.ncbi.nlm.nih.gov/37847433/" target="_blank" rel="noopener">published</a> in Discover Oncology.
&#8220;Previous clinic models for patients with [HCC] receiving [TACE] mainly focused on the overall survival, whereas a simple-to-use tool for predicting the response to the first TACE and the management of risk classification before TACE [is] lacking,&#8221; the researchers noted.
To develop a manually calculated scoring system, the researchers analyzed 437 patients with HCC who underwent TACE treatment. The population of interest was then randomly allocated into 2 groups: a training group comprising 350 patients and a validation group comprising 77 patients. The authors noted that 45 patients with HCC who had recently undergone TACE treatment were used to validate the model&#8217;s efficacy and applicability. The factors selected for the predictive model were based on the results of the LASSO analyses. Overall, researchers tested the discrimination, calibration ability, and clinic utility of the models in both the training and validation groups.
A model incorporating 3 objective imaging characteristics and 2 indicators of liver function demonstrated robust discrimination, with good calibration and area under the receiver operating characteristic curve scores of 0.735, 0.706, and 0.884 in the training group and validation groups. Moreover, the model successfully classified patients into low-risk, median-risk, and high-risk groups based on the calculated score, with rates of no response to TACE of 26.3%, 40.2%, and 76.8%, respectively.
The researchers concluded that this model &#8220;may be a useful and layered management tool for patients with HCC undergoing TACE.&#8221;

Amit Mahipal, MD

First-line Atezolizumab With Bevacizumab for HCC

Hepatocellular Carcinoma

Eric Singhi, MD

Cecilia Brown

Dr. Singhi on the Significance of the IASLC 2024 World Conference on Lung Cancer

WCLC 2024

Leah Pyter, PhD

Study Finds Chemotherapy Disrupts Gut Microbiome in Patients With Breast Cancer

Breast Cancer

Latest News

A Prediction Model for HCC Patients Undergoing TACE

A prediction model may serve as a viable management tool for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe